Sofwave 'On the Scene' at IMCAS 2026

Sofwave on the Scene at IMCAS Paris 2026: Clinical Education, Global Dialogue and Safety-Led Conversations in Non-Invasive Tightening

Sofwave marked a strong presence at IMCAS Paris 2026, delivering a focused programme of clinical education and media engagement centred on the evolving role of non-invasive skin tightening within modern aesthetic practice.

At the heart of the brand’s activity was its international symposium, featuring Dr Jean Carruthers amid a roster of impressive international KOLs, which explored how rising use of GLP-1 medications is reshaping patient needs around facial and body skin laxity. Discussions highlighted the growing demand for non-invasive, device-led tightening solutions that deliver controlled, natural-looking results without downtime, as clinicians adapt treatment pathways for patients experiencing weight loss-related skin changes.

Speaking about the Sofwave keynote symposium, UK KOL Dr Jenny Doyle commented: 

“There has been a huge shift in the aesthetic market following the rapid rise in popularity of GLP-1 medications. What was particularly exciting about this symposium was that it addressed the real downstream effects of GLP-1 weight loss - namely skin laxity and changes in muscle tone.  We’re seeing traditional body contouring treatments such as cryolipolysis decline significantly as patients lose weight pharmacologically. The unmet need now is skin tightening. Surgery remains an option, of course, but it’s not suitable for all patients due to downtime, cost, scarring, and risk. There is a growing demand for non-invasive solutions that can support both muscle tone and skin quality alongside weight loss.”

Sofwave also hosted a French press event, bringing together an international panel of physicians to discuss safety, validation and technology choice within energy-based treatments. UK consultant oculoplastic surgeon Dr Jenny Doyle joined the panel, discussing her experiences and insights around the clinical advantages of Sofwave’s ultrasound-based skin tightening and the importance of predictable, needle-free technology options within contemporary aesthetic care.

Speaking at the press event, Dr Jenny commented:

“The FDA warning serves as an important reminder that RF microneedling devices are capable of causing harm if used incorrectly or by individuals who are not appropriately trained. It’s not a blanket condemnation of the technology, but rather a call for greater awareness, regulation, and education. One of the key advantages of Sofwave is its safety profile and consistency. The technology does not penetrate deeply enough to affect fat or cause scarring, which makes outcomes more predictable and reduces the risk of complications. Clinically, Sofwave treats a large surface area in a single session, allowing for meaningful lifting and tightening without the variability in depth seen with RF microneedling. It also avoids concerns around post-inflammatory pigmentation, particularly in darker skin types.”

Throughout the congress, Sofwave also engaged clinicians and media through booth activity, live demonstrations, and private meetings, reinforcing its commitment to education, collaboration, and evidence-informed innovation as the aesthetics industry moves further into 2026.